With its injectable biosensor technology well into the clinical development stage, Glympse Bio has its sights set on revolutionizing the way we diagnose diseases and track their progression throughout the body. Helping Glympse along its path through trials, FDA approval and beyond will be Tram Tran, M.D., who joins the Cambridge, Mass.-based company as its […]

Obsidian Therapeutics has raked in $115 million to realize the long-unfulfilled therapeutic promise of tumor-infiltrating lymphocytes (TILs). The series B gives Obsidian a shot at showing whether freeing TILs from IL-2 can finally unleash power that research has hinted at for almost 30 years. Researchers at the NIH began revealing the therapeutic potential of TILs […]

Our apologies to those who still wince when reminded of the following figures. But because these data illustrate successes, or lack thereof, of clinical trials from the past, they serve as an outcomes baseline for the future: Will future outcomes be based on the types of protocols used in the COVID-19 vaccine trials, or will […]